Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words 'Kovarik, JM' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 46 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Doyle, RL; Hertz, MI; Dunitz, JM; Loyd, JE; Stecenko, AA; Wong, RL; Chappell, KA; Brazelton, T; Kovarik, JM; Appeldingmanse, S; Dou, L; Smith, HT; Tudor, D; Morris, RE
      RAD in stable lung and heart/lung transplant recipients: Safety, tolerability, pharmacokinetics, and impact of cystic fibrosis

      JOURNAL OF HEART AND LUNG TRANSPLANTATION
    2. Kovarik, JM; Pescovitz, MD; Sollinger, HW; Kaplan, B; Legendre, C; Salmela, K; Book, BK; Gerbeau, C; Girault, D; Somberg, K
      Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients

      CLINICAL TRANSPLANTATION
    3. Levy, GA; Grant, D; Paradis, K; Campestrini, J; Smith, T; Kovarik, JM
      Pharamacokinetics and tolerability of 40-0-[2-hydroxyethyl]rapamycin in denovo liver transplant recipients

      TRANSPLANTATION
    4. Kovarik, JM; Sabia, HD; Figueiredo, J; Zimmermann, H; Reynolds, C; Dilzer, SC; Lasseter, K; Rordorf, C
      Influence of hepatic impairment on everolimus pharmacokinetics: Implications for dose adjustment

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    5. Kovarik, JM; Hsu, CH; McMahon, L; Berthier, S; Rordorf, C
      Population pharmacokinetics of everolimus in de novo renal transplant patients: Impact of ethnicity and comedications

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    6. Kovarik, JM; Nashan, B; Neuhaus, P; Clavien, PA; Gerbeau, C; Hall, ML; Korn, A
      A population pharmacokinetic screen to identify demographic-clinical covariates of basiliximab in liver transplantation

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    7. Kovarik, JM; Kahan, BD; Kaplan, B; Lorber, M; Winkler, M; Rouilly, M; Gerbeau, C; Cambon, N; Boger, R; Rordorf, C
      Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: Pharmacokinetics, exposure-responserelationships, and influence on cyclosporine

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    8. Andresen, I; Kovarik, JM; Spycher, M; Bolli, R
      Product equivalence study comparing the tolerability, pharmacokinetics, and pharmacodynamics of various human immunoglobulin-G formulations

      JOURNAL OF CLINICAL PHARMACOLOGY
    9. Kovarik, JM; Koelle, EU
      Cyclosporin pharmacokinetics in the elderly

      DRUGS & AGING
    10. Kovarik, JM; Moore, R; Wolf, P; Abendroth, D; Landsberg, D; Soulillou, JP; Gerbeau, C; Schmidt, AG
      Screening for basiliximab exposure-response relationships in renal allotransplantation

      CLINICAL TRANSPLANTATION
    11. Anderson, IF; Helve, T; Hannonen, P; Leirisalo-Repo, M; Gilboe, IM; Nissila, M; Keystone, EC; Kraag, GR; Bjorneboe, O; Chalmers, A; Dovland, H; Mueller, E; Richard, F; Whatmough, I; Schmidt, AG; Kovarik, JM
      Conversion of patients with rheumatoid arthritis from the conventional to a microemulsion formulation of cyclosporine: A double blind comparison to screen for differences in safety, efficacy, and pharmacokinetics

      JOURNAL OF RHEUMATOLOGY
    12. Kovarik, JM; Kahan, BD; Rajagopalan, PR; Bennett, W; Mulloy, LL; Gerbeau, C; Hall, ML
      Population pharmacokinetics and exposure-response relationships for basiliximab in kidney transplantation

      TRANSPLANTATION
    13. Kovarik, JM; Rigaudy, L; Guerret, M; Gerbeau, C; Rost, KL
      Longitudinal assessment of a P-glycoprotein-mediated drug interaction of valspodar on digoxin

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    14. KOVARIK JM; PURBA HS; PONGOWSKI M; GERBEAU C; HUMBERT H; MUELLER EA
      PHARMACOKINETICS OF DEXAMETHASONE AND VALSPODAR, A P-GLYCOPROTEIN (MDR1) MODULATOR - IMPLICATIONS FOR COADMINISTRATION

      Pharmacotherapy
    15. PRIMMETT DRN; LEVINE M; KOVARIK JM; MUELLER EA; KEOWN PA
      CYCLOSPORINE MONITORING IN PATIENTS WITH RENAL-TRANSPLANTS - 2-POINT OR 3-POINT METHODS THAT ESTIMATE AREA-UNDER-THE-CURVE ARE SUPERIOR TO TROUGH LEVELS IN PREDICTING DRUG EXPOSURE

      Therapeutic drug monitoring
    16. MUELLER EA; KOVARIK JM; PITTROW D
      IMPROVING THE ORAL ABSORPTION OF CYCLOSPORINE IN MALABSORBERS - A REVIEW OF THE NEORAL COMPASSIONATE NEED PROGRAM

      Transplantation proceedings
    17. KOVARIK JM; MUELLER EA; GERBEAU C; TARRAL A; FRANCHETEAU P; GUERRET M
      CYCLOSPORINE AND NONSTEROIDAL ANTIINFLAMMATORY DRUGS - EXPLORING POTENTIAL-DRUG INTERACTIONS AND THEIR IMPLICATIONS FOR THE TREATMENT OF RHEUMATOID-ARTHRITIS

      Journal of clinical pharmacology
    18. MUELLER EA; KOVARIK JM; URESIN Y; PREISIGFLUCKIGER SS; HENSEL S; LUCKER PW; HOLT B
      OPTIMIZING THE ABSORPTION OF VALSPODAR, A P-GLYCOPROTEIN MODULATOR .1. SELECTING AN ORAL FORMULATION AND EXPLORING ITS CLINICAL PHARMACOKINETICS DYNAMICS/

      Journal of clinical pharmacology
    19. KOVARIK JM; MULLER EA; RICHARD F; TETZLOFF W
      OPTIMIZING THE ABSORPTION OF VALSPODAR, A P-GLYCOPROTEIN MODULATOR .2. QUANTIFYING ITS PHARMACOKINETIC VARIABILITY AND REFINING THE BIOAVAILABILITY ESTIMATE

      Journal of clinical pharmacology
    20. KOVARIK JM; KURKI P; MUELLER E; GUERRET M; MARKERT E; ALTEN R; ZEIDLER H; GENTHSTOLZENBURG S
      DICLOFENAC COMBINED WITH CYCLOSPORINE IN TREATMENT-REFRACTORY RHEUMATOID-ARTHRITIS - LONGITUDINAL SAFETY ASSESSMENT AND EVIDENCE OF A PHARMACOKINETIC DYNAMIC INTERACTION/

      Journal of rheumatology
    21. TARR PE; LIN R; MUELLER EA; KOVARIK JM; GUILLAUME M; JONES TC
      EVALUATION OF TOLERABILITY AND ANTIBODY-RESPONSE AFTER RECOMBINANT HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (RHGM CSF) AND A SINGLE-DOSE OF RECOMBINANT HEPATITIS-B VACCINE

      Vaccine
    22. KOVARIK JM; MUELLER EA; NIESE D
      CLINICAL DEVELOPMENT OF A CYCLOSPORINE MICROEMULSION IN TRANSPLANTATION

      Therapeutic drug monitoring
    23. KOVARIK JM; RAWLINGS E; SWENY P; FERNANDO O; MOORE R; GRIFFIN PJ; FAUCHALD P; ALBRECHTSEN D; SODAL G; NORDAL K; AMLOT PL
      PROLONGED IMMUNOSUPPRESSIVE EFFECT AND MINIMAL IMMUNOGENICITY FROM CHIMERIC (CD25) MONOCLONAL-ANTIBODY SDZ-CHI-621 IN RENAL-TRANSPLANTATION

      Transplantation proceedings
    24. KOVARIK JM; MUELLER EA; RICHARD F; NIESE D; HALLORAN PF; JEFFERY J; PAUL LC; KEOWN PA
      EVIDENCE FOR EARLIER STABILIZATION OF CYCLOSPORINE PHARMACOKINETICS IN DE-NOVO RENAL-TRANSPLANT PATIENTS RECEIVING A MICROEMULSION FORMULATION

      Transplantation
    25. KOVARIK JM; KALLAY Z; MUELLER EA; VANBREE JB; ARNS W; RENNER E
      ACUTE EFFECT OF CYCLOSPORINE ON RENAL-FUNCTION FOLLOWING THE INITIAL CHANGEOVER TO A MICROEMULSION FORMULATION IN STABLE KIDNEY-TRANSPLANT PATIENTS

      Transplant international
    26. KOVARIK JM; MUELLER EA; KALLAY Z; SMITH HT; LISON AE; ARNS W; RENNER E
      CONCENTRATION-GUIDED STRATEGIES IN DRUG DEVELOPMENT - EXPERIENCE WITHA CYCLOSPORINE ANALOG IN TRANSPLANTATION

      Journal of clinical pharmacology
    27. KOVARIK JM; MUELLER EA; ZEHENDER H; DENOUEL J; CAPLAIN H; MILLERIOUX L
      MULTIPLE-DOSE PHARMACOKINETICS AND DISTRIBUTION IN TISSUE OF TERBINAFINE AND METABOLITES

      Antimicrobial agents and chemotherapy
    28. MUELLER EA; KALLAY Z; KOVARIK JM; ARNS W; RENNER E; KUTZ K
      ASSESSMENT OF GLOMERULAR-FILTRATION RATE AFTER MULTIPLE ADMINISTRATION OF A NEW ORAL FORMULATION OF CYCLOSPORINE IN CLINICALLY STABLE RENAL-TRANSPLANT PATIENTS

      Transplantation proceedings
    29. HOLT DW; MUELLER EA; KOVARIK JM; VANBREE JB; RICHARD F; KUTZ K
      SANDIMMUN NEORAL PHARMACOKINETICS - IMPACT OF THE NEW ORAL FORMULATION

      Transplantation proceedings
    30. WAHLBERG J; WILCZEK HE; FAUCHALD P; NORDAL KP; HEAF JG; OLGAARD K; HANSEN JM; LOKKEGAARD H; MUELLER EA; KOVARIK JM
      CONSISTENT ABSORPTION OF CYCLOSPORINE FROM A MICROEMULSION FORMULATION ASSESSED IN STABLE RENAL-TRANSPLANT RECIPIENTS OVER A ONE-YEAR STUDYPERIOD

      Transplantation
    31. MUELLER EA; KALLAY Z; KOVARIK JM; RICARD F; WIESINGER O; SCHMIDT K; SCHEELE J
      BILE-INDEPENDENT ABSORPTION OF CYCLOSPORINE FROM A MICROEMULSION FORMULATION IN LIVER-TRANSPLANT PATIENTS

      Transplantation
    32. MUELLER EA; KOVARIK JM; VANBREE JB; TETZLOFF W; GREVEL J; KUTZ K
      IMPROVED DOSE LINEARITY OF CYCLOSPORINE PHARMACOKINETICS FROM A MICROEMULSION FORMULATION

      Pharmaceutical research
    33. MUELLER EA; KOVARIK JM; VANBREE JB; GREVEL J; LUCKER PW; KUTZ K
      INFLUENCE OF A FAT-RICH MEAL ON THE PHARMACOKINETICS OF A NEW ORAL FORMULATION OF CYCLOSPORINE IN A CROSSOVER COMPARISON WITH THE MARKET FORMULATIONS

      Pharmaceutical research
    34. KOVARIK JM; VERNILLET L; MUELLER EA; FREIBURGHAUS R; NIEDERBERGER W; KUTZ K
      CYCLOSPORINE DISPOSITION AND METABOLITE PROFILES IN RENAL-TRANSPLANT PATIENTS RECEIVING A MICROEMULSION FORMULATION

      Therapeutic drug monitoring
    35. KOVARIK JM; MUELLER EA; VANBREE JB; ARNS W; RENNER E; KUTZ K
      WITHIN-DAY CONSISTENCY IN CYCLOSPORINE PHARMACOKINETICS FROM A MICROEMULSION FORMULATION IN RENAL-TRANSPLANT PATIENTS

      Therapeutic drug monitoring
    36. HOLT DW; MUELLER EA; KOVARIK JM; VANBREE JB; KUTZ K
      THE PHARMACOKINETICS OF SANDIMMUN-NEORAL - A NEW ORAL FORMULATION OF CYCLOSPORINE

      Transplantation proceedings
    37. MUELLER EA; KOVARIK JM; KUTZ K
      MINOR INFLUENCE OF A FAT-RICH MEAL ON THE PHARMACOKINETICS OF A NEW ORAL FORMULATION OF CYCLOSPORINE

      Transplantation proceedings
    38. VERNILLET L; KOVARIK JM; FREIBURGHAUS R; SCHAUB P; MUELLER EA; NIEDERBERGER W; ZEHENDER H
      BLOOD CYCLOSPORINE-A AND METABOLITE KINETIC PROFILES AFTER ADMINISTRATION OF SANDIMMUNE SOFT GELATIN CAPSULES AND NEORAL IN TRANSPLANT RECIPIENTS

      Transplantation proceedings
    39. KOVARIK JM; MUELLER EA; VANBREE JB; FLUCKIGER SS; LANGE H; SCHMIDT B; BOESKEN WH; LISON AE; KUTZ K
      CYCLOSPORINE PHARMACOKINETICS AND VARIABILITY FROM A MICROEMULSION FORMULATION - A MULTICENTER INVESTIGATION IN KIDNEY-TRANSPLANT PATIENTS

      Transplantation
    40. MUELLER EA; KOVARIK JM; VANBREE JB; LISON AE; KUTZ K
      PHARMACOKINETICS AND TOLERABILITY OF A MICROEMULSION FORMULATION OF CYCLOSPORINE IN RENAL-ALLOGRAFT RECIPIENTS - A CONCENTRATION-CONTROLLEDCOMPARISON WITH THE COMMERCIAL FORMULATION

      Transplantation
    41. KOVARIK JM; MUELLER EA; VANBREE JB; TETZLOFF W; KUTZ K
      REDUCED INTERINDIVIDUAL AND INTRAINDIVIDUAL VARIABILITY IN CYCLOSPORINE PHARMACOKINETICS FROM A MICROEMULSION FORMULATION

      Journal of pharmaceutical sciences
    42. KOVARIK JM; MUELLER EA; JOHNSTON A; HITZENBERGER G; KUTZ K
      BIOEQUIVALENCE OF SOFT GELATIN CAPSULES AND ORAL SOLUTION OF A NEW CYCLOSPORINE FORMULATION

      Pharmacotherapy
    43. KOVARIK JM; MUELLER EA; GABER M; JOHNSTON A; JAHNCHEN E
      PHARMACOKINETICS OF CYCLOSPORINE AND STEADY-STATE ASPIRIN DURING COADMINISTRATION

      Journal of clinical pharmacology
    44. MUELLER EA; KOVARIK JM; KOELLE EU; MERDJAN H; JOHNSTON A; HITZENBERGER G
      PHARMACOKINETICS OF CYCLOSPORINE AND MULTIPLE-DOSE DICLOFENAC DURING COADMINISTRATION

      Journal of clinical pharmacology
    45. SOMMERS DK; KOVARIK JM; MEYER EC; VANWYK M; SNYMAN JR; BLOM M; OTT S; GRASS P; KUTZ K
      EFFECTS OF DICLOFENAC ON ISRADIPINE PHARMACOKINETICS AND PLATELET-AGGREGATION IN VOLUNTEERS

      European Journal of Clinical Pharmacology
    46. BIESMA B; POKORNY R; KOVARIK JM; DUFFY FA; WILLEMSE PHB; MULDER NH; DEVRIES EGE
      PHARMACOKINETICS OF RECOMBINANT HUMAN INTERLEUKIN-3 ADMINISTERED SUBCUTANEOUSLY AND BY CONTINUOUS INTRAVENOUS-INFUSION IN PATIENTS AFTER CHEMOTHERAPY FOR OVARIAN-CANCER

      Cancer research


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 06/08/20 alle ore 16:29:01